Balyasny Asset Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Balyasny Asset Management’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,598	Closed	-$111K	–	2111
2018 Q2	$111K	Buy	2,598 +1,487	+134%	+$68.1K	﹤0.01%	1704
2018 Q1	$73K	Buy	+1,111	New	+$78.7K	﹤0.01%	1850
2017 Q2	–	Sell	-22,137	Closed	-$4.8M	–	1816
2017 Q1	$4.8M	Buy	+22,137	New	+$3.16M	0.02%	710
2016 Q4	–	Sell	-8,728	Closed	-$1.18M	–	1518
2016 Q3	$1.18M	Buy	8,728 +395	+5%	+$39.2K	0.01%	666
2016 Q2	$845K	Buy	+8,333	New	+$1.03M	0.01%	761
2014 Q2	–	Sell	-3,333	Closed	-$852K	–	801
2014 Q1	$852K	Buy	+3,333	New	+$1.02M	0.01%	526

Other funds holding LUMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management's LUMO Position: Q3 2018 in Review

Balyasny Asset Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2018, closing a stake of 2,598 shares — an estimated $111K sold.

Balyasny Asset Management first reported a position in LUMO in Q1 2014 and held it in 6 quarters. The position peaked at $4.8M in Q1 2017. 92 funds tracked by Wall St. Rank hold LUMO as of Q3 2018.

Balyasny Asset Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
Balyasny Asset Management sold 2,598 Lumos Pharma, Inc. Common Stock shares in Q3 2018, an estimated $111K.
Balyasny Asset Management first reported a position in Lumos Pharma, Inc. Common Stock in Q1 2014 and held it in 6 quarters.
Balyasny Asset Management's Lumos Pharma, Inc. Common Stock position peaked at $4.8M in Q1 2017.
92 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2018.

Based on Balyasny Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.